Latest Frazier Life Sciences Management, L.P. Stock Portfolio
Frazier Life Sciences Management, L.P. Performance:
2024 Q3: 5.18%YTD: 13.92%2023: 13.08%
Performance for 2024 Q3 is 5.18%, and YTD is 13.92%, and 2023 is 13.08%.
About Frazier Life Sciences Management, L.P. and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Frazier Life Sciences Management, L.P. reported an equity portfolio of $2.5 Billions as of 30 Sep, 2024.
The top stock holdings of Frazier Life Sciences Management, L.P. are MIRM, NAMS, PHAT. The fund has invested 10.3% of it's portfolio in MIRUM PHARMACEUTICALS INC and 8.6% of portfolio in NEWAMSTERDAM PHARMA COMPANY.
The fund managers got completely rid off CEREVEL THERAPEUTICS HLDNG I (CERE), APPLIED THERAPEUTICS INC (APLT) and AN2 THERAPEUTICS INC (ANTX) stocks. They significantly reduced their stock positions in PEPGEN INC (PEPG), EDGEWISE THERAPEUTICS INC (EWTX) and VAXCYTE INC (PCVX). Frazier Life Sciences Management, L.P. opened new stock positions in MBX BIOSCIENCES INC, ALKERMES PLC (ALKS) and DAY ONE BIOPHARMACEUTICALS I (DAWN). The fund showed a lot of confidence in some stocks as they added substantially to ELEVATION ONCOLOGY INC (ELEV), DESIGN THERAPEUTICS INC (DSGN) and ULTRAGENYX PHARMACEUTICAL IN (RARE).
The top stock holdings of Frazier Life Sciences Management, L.P. are MIRM, NAMS, PHAT. The fund has invested 10.3% of it's portfolio in MIRUM PHARMACEUTICALS INC and 8.6% of portfolio in NEWAMSTERDAM PHARMA COMPANY.
The fund managers got completely rid off CEREVEL THERAPEUTICS HLDNG I (CERE), APPLIED THERAPEUTICS INC (APLT) and AN2 THERAPEUTICS INC (ANTX) stocks. They significantly reduced their stock positions in PEPGEN INC (PEPG), EDGEWISE THERAPEUTICS INC (EWTX) and VAXCYTE INC (PCVX). Frazier Life Sciences Management, L.P. opened new stock positions in MBX BIOSCIENCES INC, ALKERMES PLC (ALKS) and DAY ONE BIOPHARMACEUTICALS I (DAWN). The fund showed a lot of confidence in some stocks as they added substantially to ELEVATION ONCOLOGY INC (ELEV), DESIGN THERAPEUTICS INC (DSGN) and ULTRAGENYX PHARMACEUTICAL IN (RARE).
Frazier Life Sciences Management, L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that Frazier Life Sciences Management, L.P. made a return of 5.18% in the last quarter. In trailing 12 months, it's portfolio return was 33.16%.
New Buys
| Ticker | $ Bought |
|---|---|
| mbx biosciences inc | 155,499,000 |
| ascendis pharma a/s | 19,908,000 |
| alkermes plc | 16,125,900 |
| oruka therapeutics inc | 11,699,300 |
| lexeo therapeutics inc | 11,307,100 |
| day one biopharmaceuticals i | 9,606,890 |
| nuvation bio inc | 2,789,760 |
| pieris pharmaceuticals inc | 266,869 |
New stocks bought by Frazier Life Sciences Management, L.P.
Additions
| Ticker | % Inc. |
|---|---|
| elevation oncology inc | 102 |
| design therapeutics inc | 58.35 |
| ultragenyx pharmaceutical in | 49.11 |
| agios pharmaceuticals inc | 19.75 |
| erasca inc | 19.58 |
| immatics n.v | 17.55 |
| mereo biopharma group plc | 15.82 |
| newamsterdam pharma company | 5.14 |
Additions to existing portfolio by Frazier Life Sciences Management, L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| pepgen inc | -53.24 |
| edgewise therapeutics inc | -24.07 |
| vaxcyte inc | -15.39 |
| tyra biosciences inc | -12.16 |
| rocket pharmaceuticals inc | -4.84 |
Frazier Life Sciences Management, L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| applied therapeutics inc | -10,676,200 |
| an2 therapeutics inc | -4,491,110 |
| cerevel therapeutics hldng i | -16,069,800 |
| metagenomi inc | -1,002,420 |
Frazier Life Sciences Management, L.P. got rid off the above stocks
Sector Distribution
Frazier Life Sciences Management, L.P. has about 86% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 86 |
| Others | 14 |
Market Cap. Distribution
Frazier Life Sciences Management, L.P. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 41.5 |
| MID-CAP | 30.8 |
| UNALLOCATED | 24.4 |
| MICRO-CAP | 3.3 |
Stocks belong to which Index?
About 67% of the stocks held by Frazier Life Sciences Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 67 |
| Others | 33 |
Frazier Life Sciences Management, L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P. has 53 stocks in it's portfolio. About 59.9% of the portfolio is in top 10 stocks. HLVX proved to be the most loss making stock for the portfolio. PHAT was the most profitable stock for Frazier Life Sciences Management, L.P. last quarter.
Last Reported on: 15 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACAD | acadia pharmaceuticals inc | 0.29 | 470,338 | 7,233,800 | unchanged | 0.00 | ||
| ACRS | aclaris therapeutics inc | 0.01 | 264,377 | 304,034 | unchanged | 0.00 | ||
| ADVM | adverum biotechnologies inc | 0.30 | 1,069,240 | 7,506,090 | unchanged | 0.00 | ||
| AGIO | agios pharmaceuticals inc | 1.86 | 1,044,150 | 46,391,800 | added | 19.75 | ||
| ALKS | alkermes plc | 0.65 | 576,129 | 16,125,900 | new | |||
| ALLO | allogene therapeutics inc | 0.32 | 2,867,750 | 8,029,700 | unchanged | 0.00 | ||
| ANAB | anaptysbio inc | 2.97 | 2,209,190 | 74,007,800 | added | 2.01 | ||
| ANTX | an2 therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLT | applied therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARQT | arcutis biotherapeutics inc | 3.28 | 8,785,280 | 81,703,100 | unchanged | 0.00 | ||
| ARVN | arvinas inc | 0.28 | 285,331 | 7,027,700 | unchanged | 0.00 | ||
| AUTL | autolus therapeutics plc | 0.67 | 4,623,320 | 16,782,700 | unchanged | 0.00 | ||
| BBIO | bridgebio pharma inc | 3.84 | 3,760,460 | 95,741,200 | added | 3.52 | ||
| CERE | cerevel therapeutics hldng i | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| COGT | cogent biosciences inc | 0.41 | 936,576 | 10,115,000 | unchanged | 0.00 | ||
| DAWN | day one biopharmaceuticals i | 0.38 | 689,655 | 9,606,890 | new | |||
| DSGN | design therapeutics inc | 0.41 | 1,892,550 | 10,181,900 | added | 58.35 | ||
| ELEV | elevation oncology inc | 0.14 | 5,993,580 | 3,595,550 | added | 102 | ||
| ERAS | erasca inc | 2.12 | 19,391,700 | 52,939,300 | added | 19.58 | ||
| ETNB | 89bio inc | 0.30 | 1,000,000 | 7,400,000 | unchanged | 0.00 | ||